<DOC>
	<DOC>NCT00502112</DOC>
	<brief_summary>This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycles of combination therapy.</brief_summary>
	<brief_title>A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Disease confirmation of MDS. 2. Between 5% and 30% blasts in the bone marrow. 3. Received treatment for cytopenias within 2months 4. ECOG ≤ 2. 1. Received prior therapy with lenalidomide, gemtuzumab ozogamicin (Mylotarg®). 2. Received chemotherapy/radiotherapy within 4 weeks of study registration. 3. Received prior bone marrow transplant. 4. 5q chromosomal deletion in malignant cells.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lintuzumab</keyword>
	<keyword>Antigens, CD33</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Preleukemia</keyword>
</DOC>